BIOCRYST PHARMACEUTICALS INC
BCRXNasdaq
$9.29
↑ +2.0%Jul 17 close · end-of-day
Price
1Y↑ +8.1%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$2.3B
Enterprise Value
$2.4B
P/E
—
P/S
2.5
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
$885.7M
Net Income (TTM)
-$458.0M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
-43.1%
Net Margin
-51.7%
ROE
82.7%
ROIC
—
Debt / Equity
-0.7
Net Cash
-$156.8M
Return 1Y
+6.8%
Company profile
BioCryst Pharmaceuticals, Inc. discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II clinical trial for complement-mediated diseases. Galidesivir, a RNA dependent-RNA polymerase inhibitor, is in clinical trial to treat various RNA viruses, including Marburg, Yellow Fever, Ebola,
- CEO
- Jon P. Stonehouse
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 530
- Headquarters
- North Carolina
- Website
- biocryst.com
Management & directors
- Barnes Alane PChief Legal Officer
- Menon SandeepChief R&D Officer
- Gayer Charles KPresident and CCO
- Stonehouse Jon PChief Executive Officer
- Ghias BabarCFO & Head of Corp Development
Roles derived from SEC Form 4 filings.
Earnings
BCRX Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$156.4M↑ +7.5%
Diluted EPS-$2.98—
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $17.8M | $157.2M | $270.8M | $331.4M | $450.7M | $874.8M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$174.8M | -$177.7M | -$148.4M | -$103.7M | -$2.5M | $341.0M |
| Net income | -$182.8M | -$184.1M | -$247.1M | -$226.5M | -$88.9M | $263.9M |
| Diluted EPS | -$1.09 | -$1.03 | -$1.33 | -$1.18 | -$0.43 | $1.21 |
| Operating cash flow | -$135.1M | -$142.2M | -$161.8M | -$95.1M | -$52.0M | $347.4M |
| Free cash flow | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -981.1% | -113.1% | -54.8% | -31.3% | -0.6% | 39.0% |
| Net margin | -1026.4% | -117.1% | -91.2% | -68.4% | -19.7% | 30.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $109.3M | $117.1M | $131.5M | $145.5M | $163.4M | $159.4M | $406.6M | $156.4M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $8.8M | $7.7M | -$4.5M | $21.2M | $29.8M | $29.6M | $260.4M | -$701.6M |
| Net income | -$12.7M | -$14.0M | -$26.8M | $32,000.00 | $5.1M | $12.9M | $245.8M | -$721.8M |
| Diluted EPS | -$0.06 | -$0.07 | -$0.13 | $0.00 | $0.02 | $0.06 | $1.13 | -$2.98 |
| Operating cash flow | -$1.4M | $8.2M | -$5.2M | -$27.5M | $41.3M | $41.6M | $292.0M | -$61.8M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | 8.0% | 6.6% | -3.4% | 14.6% | 18.2% | 18.6% | 64.0% | -448.6% |
| Net margin | -11.6% | -12.0% | -20.4% | 0.0% | 3.1% | 8.1% | 60.5% | -461.5% |
Company news
Jul 9, 2026
Jul 8, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-11 | Milne Jill C. | Award | 15,294 | $0.00 | $0.00 | filing |
| 2026-06-11 | Galson Steven K | Award | 15,294 | $0.00 | $0.00 | filing |
| 2026-06-11 | LEVIN ALAN G | Award | 15,294 | $0.00 | $0.00 | filing |
| 2026-06-11 | Frank Steven | Award | 15,294 | $0.00 | $0.00 | filing |
| 2026-06-11 | SANDERS MACHELLE | Award | 15,294 | $0.00 | $0.00 | filing |
| 2026-06-11 | MILANO VINCENT | Award | 15,294 | $0.00 | $0.00 | filing |
| 2026-06-11 | Stonehouse Jon P | Award | 15,294 | $0.00 | $0.00 | filing |
| 2026-06-11 | McKee Amy E | Award | 15,294 | $0.00 | $0.00 | filing |
| 2026-06-11 | HEGGIE THERESA | Award | 15,294 | $0.00 | $0.00 | filing |
| 2026-05-29 | Milne Jill C. | Award | 1,262 | $8.91 | $11,244.42 | filing |
| 2026-05-29 | Frank Steven | Award | 1,262 | $8.91 | $11,244.42 | filing |
| 2026-05-29 | MILANO VINCENT | Award | 1,122 | $8.91 | $9,997.02 | filing |
| 2026-05-29 | Stonehouse Jon P | Award | 631 | $8.91 | $5,622.21 | filing |
| 2026-05-29 | McKee Amy E | Award | 631 | $8.91 | $5,622.21 | filing |
| 2026-05-18 | McKee Amy E | Sale | 11,180 | $8.97 | $100,284.60 | filing |
| 2026-05-13 | Barnes Alane P· Chief Legal Officer | Sale | 62,500 | $9.54 | $596,250.00 | filing |
| 2026-05-13 | Barnes Alane P· Chief Legal Officer | Option exercise | 62,500 | $5.04 | $315,000.00 | filing |
| 2026-04-06 | Menon Sandeep· Chief R&D Officer | Award | 205,150 | $0.00 | $0.00 | filing |
| 2026-03-20 | HEGGIE THERESA | Sale | 49,933 | $10.11 | $504,822.63 | filing |
| 2026-03-20 | HEGGIE THERESA | Option exercise | 49,933 | $6.30 | $314,577.90 | filing |
| 2026-03-16 | Barnes Alane P· Chief Legal Officer | Sale | 150,000 | $9.15 | $1.4M | filing |
| 2026-03-16 | Barnes Alane P· Chief Legal Officer | Option exercise | 150,000 | $5.51 | $826,500.00 | filing |
| 2026-03-02 | Stonehouse Jon P | D | 305,995 | $8.64 | $2.6M | filing |
| 2026-03-02 | Stonehouse Jon P | Option exercise | 305,995 | $3.22 | $985,303.90 | filing |
| 2026-02-27 | Frank Steven | Award | 1,285 | $8.75 | $11,243.75 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.